AVI BiopharmaAVII is already on the run, targeting $1.60 but poised to go a lot higher. This was a $25 stock back in 2000, when flu was still a three letter word.
AVI BioPharma, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products based on antisense and cancer immunotherapy technology. The company's products under various development stages comprise AVI-4658, a Phase I human clinical trial product to restore, prevent, or slow deterioration of muscle function; AVI-5038, a preclinical stage product to skip exon 50 and restore a range of associated mutations; AVI-5126, a Phase II clinical trial product for the treatment of cardiovascular restenosis; and AVI-6002 and AVI-6003, which are in Phase I clinical trials to treat diseases caused by Dengue, Ebola, Marburg, and Junín viruses. It has strategic alliances with Chiron Corporation; Cook Group Incorporated; Ercole Biotech, Inc.; Eleos Inc.; Charley's Fund, Inc.; and the United States Department of Defense. The company was founded in 1980 and is based in Corvallis, Oregon.
All these charts are beginning to look the same, the start of impulsive up moves, a perfect storm for traders like us. BCRX has some strong fundamentals to go along with all of the above:
That brings us to five stocks to start off the Swine Flu Basket. Here they are listed along with respective market caps and share prices as of Friday's close: